Disturbed EEG Sleep, Paranoid Cognition and Somatic Symptoms Identify Veterans With Post-Traumatic Stress Disorder

Harvey Moldofsky
Lorne Rothman
Robert Kleinman
Shawn G. Rhind
Don Richardson

Western University, Don.Richardson@sjhc.london.on.ca

Follow this and additional works at: https://ir.lib.uwo.ca/osircpub

Part of the Mental and Social Health Commons, and the Social and Behavioral Sciences Commons

Citation of this paper:
Moldofsky, Harvey; Rothman, Lorne; Kleinman, Robert; Rhind, Shawn G.; and Richardson, Don, "Disturbed EEG Sleep, Paranoid Cognition and Somatic Symptoms Identify Veterans With Post-Traumatic Stress Disorder" (2018). MacDonald Franklin OSI Research Centre. 8.
https://ir.lib.uwo.ca/osircpub/8
Disturbed EEG sleep, paranoid cognition and somatic symptoms identify veterans with post-traumatic stress disorder

Harvey Moldofsky, Lorne Rothman, Robert Kleinman, Shawn G. Rhind and J. Donald Richardson

**Background**
Chronic post-traumatic stress disorder (PTSD) behavioural symptoms and medically unexplainable somatic symptoms are reported to occur following the stressful experience of military combatants in war zones.

**Aims**
To determine the contribution of disordered EEG sleep physiology in those military combatants who have unexplainable physical symptoms and PTSD behavioural difficulties following war-zone exposure.

**Method**
This case-controlled study compared 59 veterans with chronic sleep disturbance with 39 veterans with DSM-IV and clinician-administered PTSD Scale diagnosed PTSD who were unresponsive to pharmacological and psychological treatments. All had standardised EEG polysomnography, computerised sleep EEG cyclical alternating pattern (CAP) as a measure of sleep stability, self-ratings of combat exposure, paranoid cognition and hostility subscales of Symptom Checklist-90, Beck Depression Inventory and the Wahler Physical Symptom Inventory. Statistical group comparisons employed linear models, logistic regression and chi-square automatic interaction detection (CHAID)-like decision trees.

**Results**
Veterans with PTSD were more likely than those without PTSD to show disturbances in non-rapid eye movement (REM) and REM sleep including delayed sleep onset, less efficient EEG sleep, less stage 4 (deep) non-REM sleep, reduced REM and delayed onset to REM. There were no group differences in the prevalence of obstructive sleep apnoeas/hypopnoeas and periodic leg movements, but sleep-disturbed, non-PTSD military had more EEG CAP sleep instability. Rank order determinants for the diagnosis of PTSD comprise paranoid thinking, onset to REM sleep, combat history and somatic symptoms. Decision-tree analysis showed that a specific military event (combat), delayed onset to REM sleep, paranoid thinking and medically unexplainable somatic pain and fatigue characterise chronic PTSD. More PTSD veterans reported domestic and social misbehaviour.

**Conclusions**
Military combat, disturbed REM/non-REM EEG sleep, paranoid ideation and medically unexplained chronic musculoskeletal pain and fatigue are key factors in determining PTSD disability following war-zone exposure.

**Declaration of interest**
None.

**Copyright and usage**
© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
experience in combat zones, enabling us to separate PTSD 
symptoms alone from those that might be associated with combat 
experience alone and to assess combat experience along with other 
patient measures when building models. We measured behaviour 
symptoms, including negative cognition (depressive, hostile, 
aggressive and paranoid thinking), and chronic physical health 
concerns, including disturbances in EEG sleep physiology, sleep 
quality and medically unexplained somatic symptoms (e.g. mus-
culoskeletal pain and fatigue).

Method

Participants

The participants comprise consecutive patients referred between 
2008 and 2014 from an Operational Stress Injury (OSI) clinic of 
the Department of Veteran Affairs of Canada. The OSI clinic 
specialises in the assessment and treatment of PTSD and other 
operational stress injuries in the Canadian military and veteran 
forces (CF). The diagnosis of PTSD was determined by a psychiatrist 
employing a comprehensive psychiatric examination and the 
Clinician-Administered PTSD Scale (CAPS) for DSM-IV, where 
the CAPS mean rating was 77.38 and s.d. 21.36. To control for 
commonly disrupted and insufficient sleep problems in the 
military, we compared sleep and symptoms in CF veterans with 
persistent symptoms of PTSD with CF personnel without a history 
PTSD who complained of chronic insomnia. This latter group 
of participants were referred from Canadian Department of 
National Defence (DND) medical ambulatory clinics for diagnostic 
assessment of a possible chronic primary sleep disorder such as 
sleep apnoea or restless legs/sleep-related periodic limb movement 
disorder.

The participants consented to be assessed in the Centre for 
Sleep and Chronobiology in Toronto for specialised comprehen-
sive sleep/wake clinical and laboratory investigations of their 
chronic treatment-resistant symptoms. The research was reviewed 
and approved by the DND, Institute of Military and Veterans 
Research Institute in association with Defence Research and 
Development Canada.

Table 1 shows the description of the participants: gender, mean 
age, mean BMI and the independent variables: combat experience (combat =yes and 0=no or unknown) and the presence of 
treatment-resistant PTSD (1=yes and 0=no) or unknown number of individuals who had previously received the 
treatment-resistant PTSD symptoms following deployment to the so-called ‘U.N. peace-keeping missions’ in 
dangerous combative environments, that is, the Balkans (Bosnia 
and Croatia) and Africa/Middle East (Suez Canal zone, Rwanda, 
Somalia and Cyprus). Six cases of PTSD occurred in sleep-
disturbed, non-combat CF patients. Distressing non-combat trau-
matic events were quite varied. They included sexual assault, 
with a major airplane crash, engagement in dangerous service 
with the military police, witness to a suicide of a soldier and 
participation in a military training exercise.

All patients with treatment-resistant PTSD (n=39) were 
functionally impaired despite psychological and lengthy pharmaco-
logical treatments (median 32.5 months (range 6–249 months)). 

All patients with PTSD had received cognitive–behavioural 
treatments, which included trauma-focussed behaviour therapy 
such as prolonged exposure and various types of psychological 
support, for example, individual, marital, family counselling and 
group therapies.

At the time of the sleep study, patients with PTSD were 
taking at least two drug class combinations of antipsychotics (e.g. 
risperidone, quetiapine, aripiprazole; n=12), various antidepress-
sants (e.g. mirtazapine, bupropion, venlafaxine, citalopram; n=34), 
anticonvulsant mood modulators (sodium valproate or topiramate; 
n=13), and benzodiazepine sedative hypnotics (n=8). In compar-
ison with the patients with PTSD, the 59 with unremitting sleep 
problems and no PTSD used fewer antidepressants (n=16), antic-
convulsants (n=4), antipsychotics (n=5) and sedative hypnotics 
(n=1) (all χ² test, P<0.05). Figure 1 and Table 1 provide a detailed description of the groups of participants, with and without PTSD, their use of 
classes of medications and whether or not they had been exposed to 
combat. The medical records that were made available did not 
 specify the psychotropic medications before their treatments at 
the time of the polysomnographic sleep study. In particular, of the 
unknown number of individuals who had previously received the 
alpha1-adrenergic receptor blocker (prazosin) for disturbing 
dreams, only two participants continued to find that this drug 
satisfactorily reduced their recurrent nightmares. Moreover, the 
psychotropic treatments were not withdrawn to avoid potential 
adverse effects and permit full cooperation of the patients to participate 
in the various physiological and psychological procedures.

In addition, to the psychotropic drugs shown in Table 1, other 
medications that were consumed include the following.

- Patients with PTSD received pain medication (opiates: 3; 
NSAIDs: 6). Sixteen patients received medication for

Table 1 Sample sizes, participant descriptions and drug use

<table>
<thead>
<tr>
<th></th>
<th>PTSD – yes</th>
<th>Combat – yes</th>
<th>PTSD – NO</th>
<th>Combat – no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of participants</td>
<td>33</td>
<td>6</td>
<td>28</td>
<td>31</td>
</tr>
<tr>
<td>Number of females</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Number of males</td>
<td>33</td>
<td>6</td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>44.4</td>
<td>46.8</td>
<td>40.5</td>
<td>41.6</td>
</tr>
<tr>
<td>Mean BMI</td>
<td>30.1</td>
<td>32.5</td>
<td>30.1</td>
<td>32.5</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>27</td>
<td>7</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>10</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Prazosin</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
cardiovascular problems. Three patients were treated for type 2 diabetes.

- Those without PTSD were prescribed more NSAIDs (n=11) and no opiates, but similar cardiovascular drugs (n=13) and antidiabetic drugs (n=4).

Those individuals who had been previously identified by the military physicians as having problems with alcohol and/or substance abuse/dependency had been treated for their condition(s) before the time of referral for their sleep study. For this study, all participants completed a self-rated standardised questionnaire on the types, amount and frequency of use of alcohol and recreational drugs over the previous year and during 2 weeks before their sleep study. During the 2 weeks before the sleep study, neither group abused alcohol and there were no differences in their alcohol habits. During the previous year, eight patients with PTSD used cannabis, whereas none of the patients without PTSD used cannabis (χ² test, P<0.01). Within the 2 weeks before the sleep study, only two patients with PTSD had occasionally taken cannabis drugs, whereas none in the sleep-disordered group used cannabis drugs (χ² test, P=NS).

The individuals with and without PTSD completed psychological and physical symptom self-reports before a single overnight EEG sleep study. Because sleep disturbance has the potential to promote negative cognitions such as irritability, aggressive behaviour, paranoid and depressive thinking that may occur with PTSD,6–8 we employed the Symptom Checklist-90 (SCL-90) subscales for hostility and paranoid thinking9,10 and the Beck Depression Inventory (BDI).11,12 Physical symptoms were self-rated from 1 to 5 with the Wahler Physical Symptom Inventory (WPSI).11,12,13 The number of symptoms self-rated as 4 or 5 on the WPSI scale (corresponding to ‘about twice a week’ or ‘nearly every day’) was tallied to determine the prevalence of troublesome symptoms. Frequency of regional pain symptoms,13 severity of fatigue (range from 1 ‘full of energy’ to 7 ‘totally physically exhausted’),14 and Stanford Sleepiness Scale15,16 were self-rated before and after the overnight sleep.

The frequency of sleep-related behavioural disturbances during the previous 2 months was rated on the Sleep–Wake questionnaire with a graded scale of 0 – 3 (0=never, 1=sometimes, 2=often and 3=always). The behavioural disturbances during sleep included frequency of awakening during the night because of nightmares or unpleasant dreams, told that you had screamed or shouted and disturbing (bad) dreams during sleep. Abnormal cognition included self-ratings of frequency of harmful behavioural to self and others noted in BDI Q9 (10): thoughts of killing self-rated on a scale of 0–3. Abnormal temper outbursts that could not be controlled included urges to beat, injure or harm someone; urges to break or smash things; shouting or throwing things (questions from the SCL-90, n=11) and no opiates, but similar cardiovascular drugs (n=13) and antidiabetic drugs (n=4).

Those without PTSD were prescribed more NSAIDs (n=11) and no opiates, but similar cardiovascular drugs (n=13) and antidiabetic drugs (n=4).

Patients treated for type 2 diabetes.

Data analyses

MANOVAs were fit into four groups of dependent variables. These included PSG and sleep EEG CAP indices; self-ratings of behaviour, including negative cognition; pre- and post-PSG sleepiness and fatigue; and physical symptom severity. Combat experiences (Combat 1=yes, 0=no or unknown) were the independent variables that were compared to whether or not they had treatment-resistant PTSD (PTSD 1=yes, 0=no) (see Table 1). Because there were only six patients with PTSD=1 and Combat=0, we did not test for PTSD × Combat experience interactions. EEG sleep measures included sleep architecture and computerised measure of EEG sleep stability, that is, sleep EEG CAP rate. MANOVA permitted the testing of the significance of suites of measures, while accounting for relationships among the dependent variables as well as the relationships between independent and dependent variables. Initial data exploration showed skewed distributions, and outliers, particularly for the sleep physiology measures. Normality assumptions were likely violated. For significance testing, MANOVA and ANOVA models were fit to ranked measures; tests on ranked data provided non-parametric tests.25–28 All inferences were based on these ranked non-parametric tests. Because multiple testing inflates Type 1 error, or the probability of rejecting the null hypothesis when true, P-values from ANOVAs were adjusted for multiple testing within each of the four independent variable groups by the adaptive step-down Holm method.29 This method controlled for the error rate within a family of tests (family-wise error). The test does not assume independence between the various dependent variables in these ANOVAs.

We used three methods to identify distinguishing characteristics of PTSD and non-PTSD patients: canonical discriminant analysis (CDA), logistic regression and decision trees. PTSD was the dependent variable. Patient measures and combat experience were the independent variables.

We fitted a chi-square automatic interaction detection (CHAID)-like decision-tree algorithm by SAS Enterprise Miner.28 The CHAID approach finds splitting rules that create pure segments of data by a chi-squared test of association with a significance cut-off (alpha of 0.05), where all P-values are adjusted for multiple testing by a Bonferroni method. Missing values were addressed through multiple imputations by the predictive mean matching method, which is more appropriate for non-normal measures.29,30 BDI was excluded from decision-tree and regression modelling because this self-rated test includes both somatic symptoms such as sleep, pain and fatigue, and abnormal cognitive behavioural data.

**Results**

Patients with PTSD differed from patients without PTSD in prevalence of suites of physical and behavioural health problems, while controlling for the effects of combat exposure. MANOVA tests showed significant differences between patients with PTSD and without PTSD on sleep measures (P<0.01), psychological symptoms self-reports (P<0.0001) and physical symptoms self-reports (P<0.01). The MANOVA test showed no significant difference between PTSD and non-PTSD on subtypes of sleep EEG CAP measures (P>0.05).
While controlling for the effects of combat exposure, individual ANOVAs showed differences between PTSD and non-PTSD groups in their distributions of onset to EEG sleep, sleep efficiency, EEG stage 4%, REM sleep onset latency, REM% and EEG CAP indices measures including CAP frequency, $\text{CAPA}_{23}/\text{CAPA}_{12}+\text{A}_{23}$ (see Table 2). Those with PTSD took longer to fall asleep, had less efficient sleep (i.e. less time asleep relative to time in bed), less deep (stage 4) sleep, lower percent of time in REM sleep and a prolonged delay to onset of REM sleep. The higher CAP frequency index in the non-PTSD group is consistent with their complaint of chronic poor quality of sleep in the absence of a specific combat-related traumatic experience. These sleep EEG differences may be influenced by more frequent use by the PTSD group of psychotropic drugs.

There were no group differences in prevalence of primary sleep disorders such as obstructive sleep apnoea or sleep-related periodic limb movements (PLM). The prevalence of patients with PTSD with an index of obstructive sleep apnoea/hypopnoeas per hour of sleep $>5$ per hour ($n=35$) did not differ from patients without PTSD ($n=25$, $\chi^2$=NS). Furthermore, there were no statistical differences in their frequencies of sleep EEG arousals from sleep apnoea/hypopnoeas or with sleep-related PLM (see Table 2).

Behavioural disturbances during sleep were more common among the PTSD veterans. Of the 39 patients with PTSD, 32 were more likely to be awakened by nightmares versus 11 of 59 patients among the PTSD veterans. Of the 39 patients with PTSD, 32 were more likely to misbehave during sleep ($\chi^2$ test, $P<0.05$). Twenty-one patients with PTSD versus six patients without PTSD reported screaming or shouting during sleep ($\chi^2$ test, $P<0.05$). Seven of those in the combat-related PTSD group also reported inadvertently striking, but not seriously injuring, their partner during sleep, whereas none of the non-PTSD group described any abnormal sleep-related behaviour.

Patients with PTSD had greater mean ratings on the WPSI with more frequent physical problems (commonly musculoskeletal pain and post-sleep fatigue) (Table 3). Patients with PTSD described significantly more BDI depressive symptoms (see Table 4). Further, seven patients with PTSD reported suicidal intentions, whereas none of the patients without PTSD reported suicidal intentions.

More patients with PTSD reported hostility and paranoid notions on the SCL-90 (Table 4). Nineteen participants reported domestic and/or violent social behaviour with three being charged and arrested for assaultive behaviour. In contrast, none of the non-combat non-PTSD patients reported any form of social misbehaviour ($\chi^2$ test, $P<0.001$).

CDA and, in particular, logistic regression and decision trees identified the most salient combinations of measures that characterise PTSD. All five runs of CDA, which used multiply imputed data sets, showed significant discriminant functions ($P<0.001$). Excluding combat exposure, the top six variables that are most correlated ($|r|>0.4$) with these functions and were the most discriminating characteristics of PTSD, comprise the following features: BDI total score, paranoid score, REM onset latency, SCL-90 hostility scale score, WPSI symptom score and reduced REM$%$ sleep. Regression models that minimise Schwarz criteria reveal that PTSD is described by REM onset latency, paranoid score and combat exposure. Individuals with combat experience had 4.7 times the odds of having PTSD compared to those without combat exposure. Because selective serotonin reuptake inhibitor (SSRI) and serotonin-noradrenaline reuptake inhibitor (SNRI) antidepressants may cause a delay in REM onset latency$^3$ and both antipsychotic as well as anticonvulsant neurotropic drugs may influence EEG sleep physiology, we also re-ran the selection routine while forcing these drugs as variables into the model. The selection routine chose the same variables. PTSD in these individuals is still described by REM onset latency, paranoid score and combat exposure, even while controlling for the use of antidepressant, antipsychotic and anticonvulsants.

The CHAID-like decision-tree analysis reveals the key traits that distinguish PTSD from non-PTSD and their relative importance. Paranoic score was the most important variable in the tree model, followed by REM onset latency, exposure to combat and WPSI severity score based on each measure’s contribution to impurity reduction across the tree (relative importance: 1, 0.79, 0.77 and 0.49, respectively). For individuals who were exposed to combat, longer delays to onset of REM sleep (REM onset latency$\geq7.5$ min) lead to higher propensity of exhibiting PTSD (0.79 or 79%). Lower REM onset latency and high paranoid scores ($\geq7.5$) lead to high PTSD propensity (0.857 or 85.7%), whereas low paranoid scores (<2.5) lead to low PTSD propensity. With no combat experience, PTSD is still highly probable (0.83 or 83%) with higher paranoid scores ($\geq2.5$) and higher somatic symptom ratings (WPSI$\geq11$). On the other hand, those non-combat individuals with lower paranoid and somatic symptom ratings were likely to have a low propensity for PTSD (see Fig. 1).

### Table 2  Results of ANOVAs sleep physiology measures

<table>
<thead>
<tr>
<th>Dependent</th>
<th>PTSD No</th>
<th>PTSD Yes</th>
<th>$\bar{X}$</th>
<th>SE</th>
<th>$n$</th>
<th>$\bar{X}$</th>
<th>SE</th>
<th>$n$</th>
<th>$F$</th>
<th>$p$</th>
<th>$\nu$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep onset latency (min)</td>
<td>11.9</td>
<td>1.81</td>
<td>58</td>
<td>17.38</td>
<td>2.47</td>
<td>38</td>
<td>&lt;0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>85.5</td>
<td>2.05</td>
<td>58</td>
<td>81.19</td>
<td>2.81</td>
<td>38</td>
<td>&lt;0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1 (%)</td>
<td>12.36</td>
<td>0.17</td>
<td>58</td>
<td>14.35</td>
<td>2.32</td>
<td>38</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 2 (%)</td>
<td>61.76</td>
<td>1.36</td>
<td>57</td>
<td>66.31</td>
<td>1.84</td>
<td>38</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 3 (%)</td>
<td>6.33</td>
<td>0.78</td>
<td>57</td>
<td>5.74</td>
<td>1.06</td>
<td>38</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 4 (%)</td>
<td>2.01</td>
<td>0.44</td>
<td>56</td>
<td>0.91</td>
<td>0.61</td>
<td>36</td>
<td>&lt;0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REM (%)</td>
<td>19.14</td>
<td>0.93</td>
<td>57</td>
<td>11.66</td>
<td>1.26</td>
<td>38</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REM onset latency (min)</td>
<td>124.91</td>
<td>10.61</td>
<td>56</td>
<td>205.91</td>
<td>14.69</td>
<td>35</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apnoea-hypopnoeas arousals</td>
<td>74.73</td>
<td>15.92</td>
<td>57</td>
<td>109.6</td>
<td>21.79</td>
<td>37</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLM arousals</td>
<td>17.57</td>
<td>5.16</td>
<td>57</td>
<td>32.98</td>
<td>7.27</td>
<td>36</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spontaneous arousals</td>
<td>51.48</td>
<td>4.62</td>
<td>58</td>
<td>45.25</td>
<td>6.38</td>
<td>37</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPA$_{2}$ Index Cycle</td>
<td>7.07</td>
<td>0.74</td>
<td>56</td>
<td>5.49</td>
<td>1.01</td>
<td>37</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPA$_{3}$ Index Cycle</td>
<td>9.16</td>
<td>0.99</td>
<td>56</td>
<td>6.01</td>
<td>1.34</td>
<td>37</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPA$<em>{1}/$CAPA$</em>{3}$</td>
<td>0.25</td>
<td>0.02</td>
<td>56</td>
<td>0.24</td>
<td>0.03</td>
<td>37</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total CAP Index Cycle</td>
<td>74.77</td>
<td>4.23</td>
<td>56</td>
<td>57.83</td>
<td>5.75</td>
<td>37</td>
<td>&lt;0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All $p$-values from ranked (non-parametric) tests are adjusted by the adaptive Holm method to control family-wise error rate. Least-square means (LSM) for PTSD, no (3) and yes (1), are adjusted to remove combat effects. Bold denotes significance.
This study provides provisional evidence for the key clinical and physiological sleep features that characterise veterans who remain functionally disabled with PTSD despite various drug and behavioural treatments. The results are consistent with DSM-V behavioural symptomology. The association of malfunctions of the sleeping/waking brain and medically unexplained physical symptoms with DSM-IV behavioural symptoms, identified in the MANOVA and CDA analyses, broadens our understanding of chronic PTSD. These psychological and somatic symptoms are consistent with our hypothesis that EEG sleep disturbances may provide the link between negative cognition and mood, and somatic symptoms. While ANOVA and MANOVA statistics show these symptoms to be independent of combat stressor effects, the warzone experience itself is a key characteristic of PTSD among military personnel, as shown by both the logistic regression and decision-tree models (see Fig. 1). Our decision-tree model in Fig. 1 shows that combat military service, disturbed REM sleep, paranoid thinking and medically unexplainable somatic symptoms (commonly musculoskeletal pain) characterise CF veterans with chronic PTSD. However, the regression model, while identifying combat and altered EEG sleep, did not include somatic symptoms.

Our EEG sleep results complement previous studies that show the importance of disturbances in REM and non-REM sleep. Those with chronic PTSD take longer to fall asleep, have reduced sleep efficiency, reduced stage 4 (deep) sleep, reduced and delayed onset to REM sleep.31 The delay in onset to REM sleep persists when the use of antidepressants, as well as anticonvulsants and psychotropic drugs, is statistically controlled. A previous sleep EEG study, however, that compared the sleep of drug-free combat-related PTSD patients with patients with major depression and normal individuals showed that the PTSD group had similar reduction in REM sleep and no delay in onset to REM sleep.32 Overall, our results are supportive of Germain’s hypothesis and previous EEG sleep research that disturbed REM and non-REM sleep contribute to maladaptive stress and trauma responses in PTSD.38

Ideally, further studies of sleep physiology should involve comparisons between a group of non-sleep-altering medicated sleep-disturbed individuals with PTSD and age-matched normal healthy sleepers who are accustomed to the novelty of the laboratory environment. To affirm the importance of a disorganisation of the REM/non-REM sleep as a possible key factor to the emergence of PTSD, it would be preferable to examine the EEG sleep before any drug administration, which may influence sleep physiology. The design of the research did not permit a comparative study with those who had benefited from specific pharmacological and/or behavioural treatment. A future study employing similar physiological and behavioural methodology should comprise a large group of randomised, early-identified combat-exposed versus non-combat-exposed individuals who are free of potentially sleep EEG confounding psychotropic drugs. Such research may pave the way to determining what pharmacological and behavioural methods would be useful in those early-detected post-combat military with PTSD.

Our decision to include measures of negative cognition and mood in patients with PTSD, diagnosed by DSM-IV criteria, sleep EEG CAP24 and to PTSD in the military,35 this study found no statistical differences in apnoea/hypopnoea index, sleep-related respiratory arousals or frequency of periodic limb movement arousals between those with combat-related PTSD and those with sleep-disturbed, non-PTSD military individuals.

The results are consistent with DSM-V, while identifying PTSD, a sensitive marker for sleep instability,19 may be related to their primary complaint of disturbed and unrefreshing sleep. Such differences in EEG CAP frequency are unlikely to be affected by psychotropic drugs, which reduce EEG CAP rate.37 Unlike previous studies that associate sleep-related breathing disorders to sleep EEG CAP24 and to PTSD in the military,35 this study found no statistical differences in apnoea/hypopnoea index, sleep-related respiratory arousals or frequency of periodic limb movement arousals between those with combat-related PTSD and those with sleep-disturbed, non-PTSD military individuals.

In this study of CF veterans with chronic post-combat PTSD, a prolonged delay in the onset to REM sleep is accompanied by negative mood and negative cognitive symptoms. Whereas most tricyclic, SSRI and SNRI antidepressant drugs may reduce and delay the onset to REM sleep,31 the delay in onset to REM sleep persists when the use of antidepressants, as well as anticonvulsants and psychotropic drugs, is statistically controlled. A previous sleep EEG study, however, that compared the sleep of drug-free combat-related PTSD patients with patients with major depression and normal individuals showed that the PTSD group had similar reduction in REM sleep and no delay in onset to REM sleep.32 Overall, our results are supportive of Germain’s hypothesis and previous EEG sleep research that disturbed REM and non-REM sleep contribute to maladaptive stress and trauma responses in PTSD.38

Ideally, further studies of sleep physiology should involve comparisons between a group of non-sleep-altering medicated sleep-disturbed individuals with PTSD and age-matched normal healthy sleepers who are accustomed to the novelty of the laboratory environment. To affirm the importance of a disorganisation of the REM/non-REM sleep as a possible key factor to the emergence of PTSD, it would be preferable to examine the EEG sleep before any drug administration, which may influence sleep physiology. The design of the research did not permit a comparative study with those who had benefited from specific pharmacological and/or behavioural treatment. A future study employing similar physiological and behavioural methodology should comprise a large group of randomised, early-identified combat-exposed versus non-combat-exposed individuals who are free of potentially sleep EEG confounding psychotropic drugs. Such research may pave the way to determining what pharmacological and behavioural methods would be useful in those early-detected post-combat military with PTSD.

Our decision to include measures of negative cognition and mood in patients with PTSD, diagnosed by DSM-IV criteria, sleep EEG CAP24 and to PTSD in the military,35 this study found no statistical differences in apnoea/hypopnoea index, sleep-related respiratory arousals or frequency of periodic limb movement arousals between those with combat-related PTSD and those with sleep-disturbed, non-PTSD military individuals.

In this study of CF veterans with chronic post-combat PTSD, a prolonged delay in the onset to REM sleep is accompanied by negative mood and negative cognitive symptoms. Whereas most tricyclic, SSRI and SNRI antidepressant drugs may reduce and delay the onset to REM sleep,31 the delay in onset to REM sleep persists when the use of antidepressants, as well as anticonvulsants and psychotropic drugs, is statistically controlled. A previous sleep EEG study, however, that compared the sleep of drug-free combat-related PTSD patients with patients with major depression and normal individuals showed that the PTSD group had similar reduction in REM sleep and no delay in onset to REM sleep.32 Overall, our results are supportive of Germain’s hypothesis and previous EEG sleep research that disturbed REM and non-REM sleep contribute to maladaptive stress and trauma responses in PTSD.38

Ideally, further studies of sleep physiology should involve comparisons between a group of non-sleep-altering medicated sleep-disturbed individuals with PTSD and age-matched normal healthy sleepers who are accustomed to the novelty of the laboratory environment. To affirm the importance of a disorganisation of the REM/non-REM sleep as a possible key factor to the emergence of PTSD, it would be preferable to examine the EEG sleep before any drug administration, which may influence sleep physiology. The design of the research did not permit a comparative study with those who had benefited from specific pharmacological and/or behavioural treatment. A future study employing similar physiological and behavioural methodology should comprise a large group of randomised, early-identified combat-exposed versus non-combat-exposed individuals who are free of potentially sleep EEG confounding psychotropic drugs. Such research may pave the way to determining what pharmacological and behavioural methods would be useful in those early-detected post-combat military with PTSD.

Our decision to include measures of negative cognition and mood in patients with PTSD, diagnosed by DSM-IV criteria,
In conclusion, the results of this study and previous clinical research support the notion that chronic disturbed sleep physiology, unexplained musculoskeletal pain and fatigue symptoms should be considered to be integral to irremediable post-combat PTSD. Moreover, paranoid and hostile ideation among those with post-combat PTSD, as well as in civilians with PTSD, may be a cautionary signal to the potential for antisocial behaviour. Further studies are needed to determine whether civilians who are victims of psychologically stressful events (e.g., sexual assault, non-physically injurious MVA, and industrial and environmental disasters) may demonstrate similar distinguishing features that predispose to PTSD as noted in Fig. 1.

Fig. 1  Chi-square automatic interaction detection (CHAID)-like decision tree with Beck Depression Inventory removed from analysis. The model shows the percentage (probability × 100) of post-traumatic stress disorder (PTSD), given patient combat experience, REM latency, and paranoid and Hostile Physical Symptom Inventory (WPSI) scores. Red segments show groups of patients with higher probabilities of PTSD than the overall average, whereas green segments show groups of patients with lower probabilities.

Note: Because both patients with and without PTSD are shown, the figure uses the DSM-IV PTSD terms to describe each of the segments.

References


